Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model

Translational Psychiatry

Volumn 5, Issue 9, 2015, Pages

  Li, Q ^a,b,c   Leung, Y O ^a   Zhou, I ^a   Ho, L C ^a   Kong, W ^a   Basil, P ^d   Wei, R ^e   Lam, S ^a   Zhang, X ^f   Law, A C K ^a   Chua, S E ^a   Sham, P C ^a,b   Wu, E X ^a   McAlonan, G M ^a,g  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUTAMATE DECARBOXYLASE 67; INOSITOL; N ACETYLASPARTIC ACID; OMEGA 3 FATTY ACID; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; ASPARTIC ACID; CREATINE; N-ACETYLASPARTATE; PROTECTIVE AGENT;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BRAIN BIOCHEMISTRY; CINGULATE GYRUS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DORSAL ANTERIOR CINGULATE CORTEX; EX VIVO STUDY; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; GESTATIONAL AGE; IN VIVO STUDY; INFLAMMATION; MALE; MATERNAL DISEASE; MOUSE; MOUSE MODEL; NONHUMAN; PRENATAL EXPOSURE; PREPULSE INHIBITION; PROGENY; PROTON NUCLEAR MAGNETIC RESONANCE; WEANING; ANALOGS AND DERIVATIVES; ANIMAL; DIETARY SUPPLEMENT; DRUG EFFECTS; IMMUNOLOGY; LIPID DIET; METABOLISM; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; PROCEDURES;

ANIMALS; ASPARTIC ACID; BEHAVIOR, ANIMAL; CREATINE; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; GYRUS CINGULI; INFLAMMATION; INOSITOL; MALE; MICE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PREPULSE INHIBITION; PROTECTIVE AGENTS; WEANING;

EID: 84977765580     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.126     Document Type: Article

References (92)

1. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988; 45: 189-192.
2. Braunschweig D, Krakowiak P, Duncanson P, Boyce R, Hansen RL, Ashwood P et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry 2013; 3: E277.
3. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 2011; 232: 196-199.
4. Ashwood P, Wills S, Van de Water J. The immune response in autism: A new frontier for autism research. J Leukoc Biol 2006; 80: 1-15.
5. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environment. Neurotoxicol Teratol 2013; 36: 67-81.
6. McAlonan GM, Li Q, Cheung C. The timing and specificity of prenatal immune risk factors for autism modeled in the mouse and relevance to schizophrenia. Neurosignals 2010; 18: 129-139.
7. Li Q, Cheung C, Wei R, Hui ES, Feldon J, Meyer U et al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: Evidence from MRI in a mouse model. PLoS One 2009; 4: E6354.
8. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008; 22: 469-486.
9. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biological Psychiatry 2014; 75: 332-341.
10. Li Q, Cheung C, Wei R, Cheung V, Hui ES, You Y et al. Voxel-based analysis of postnatal white matter microstructure in mice exposed to immune challenge in early or late pregnancy. Neuroimage 2010; 52: 1-8.
11. Clandinin MT. Brain development and assessing the supply of polyunsaturated fatty acid. Lipids 1999; 34: 131-137.
12. Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA et al. Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 2003; 90: 405-412.
13. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27: 10695-10702.
14. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.
15. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002; 52: 805-810.
16. Moyer CE, Delevich KM, Fish KN, Asafu-Adjei JK, Sampson AR, Dorph-Petersen KA et al. Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia. Biol Psychiatry 2012; 72: 734-743.
17. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004; 61: 649-657.
18. Glausier JR, Kimoto S, Fish KN, Lewis DA. Lower glutamic acid decarboxylase 65- kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia. Biol Psychiatry 2014; 77: 167-176.
19. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophr Bull 2009; 35: 549-562.
20. Buse J, Schoenefeld K, Munchau A, Roessner V. Neuromodulation in Tourette syndrome: Dopamine and beyond. Neurosci Biobehav Rev 2013; 37: 1069-1084.
21. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121-124.
22. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-1951.
23. Olivo SE, Hilakivi-Clarke L. Opposing effects of prepubertal low- And high-fat n-3 polyunsaturated fatty acid diets on rat mammary tumorigenesis. Carcinogenesis 2005; 26: 1563-1572.
24. Zhou IY, Ding AY, Li Q, McAlonan GM, Wu EX. Magnetic resonance spectroscopy reveals N-acetylaspartate reduction in hippocampus and cingulate cortex after fear conditioning. Psychiatry Res 2012; 204: 178-183.
25. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168-176.
26. Xin L, Gambarota G, Duarte JM, Mlynarik V, Gruetter R. Direct in vivo measurement of glycine and the neurochemical profile in the rat medulla oblongata. NMR Biomed 2010; 23: 1097-1102.
27. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008; 33: 2467-2473.
28. Du F, Cooper AJ, Thida T, Shinn AK, Cohen BM, Ongur D. Myelin and axon abnormalities in schizophrenia measured with magnetic resonance imaging techniques. Biol Psychiatry 2013; 74: 451-457.
29. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2: 322-328.
30. Schwendener S, Meyer U, Feldon J. Deficient maternal care resulting from immunological stress during pregnancy is associated with a sex-dependent enhancement of conditioned fear in the offspring. J Neurodev Disord 2009; 1: 15-32.
31. Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Bobehav Rev 2005; 29: 913-947.
32. Li Q, Wong JH, Lu G, Antonio GE, Yeung DK, Ng TB et al. Gene expression of synaptosomal-associated protein 25 (SNAP-25) in the prefrontal cortex of the spontaneously hypertensive rat (SHR). Biochim Biophys Acta 2009; 1792: 766-776.
33. Deng MY, Lam S, Meyer U, Feldon J, Li Q, Wei R et al. Frontal-subcortical protein expression following prenatal exposure to maternal inflammation. PloS One 2011; 6: E16638.
34. Aguilar-Valles A, Flores C, Luheshi GN. Prenatal inflammation-induced hypoferremia alters dopamine function in the adult offspring in rat: Relevance for schizophrenia. PloS One 2010; 5: E10967.
35. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949-1962.
36. Abbott C, Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 2006; 19: 135-139.
37. Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D et al. Neurometabolites in schizophrenia and bipolar disorder - A systematic review and meta-analysis. Psychiatry Res 2012; 203: 111-125.
38. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-A systematic review and meta-analysis. Biol Psychiatry 2011; 69: 495-503.
39. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull 2003; 29: 831-843.
40. Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 2013; 39: 1096-1104.
41. Madhavarao CN, Chinopoulos C, Chandrasekaran K. Namboodiri MAA. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem 2003; 86: 824-835.
42. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002; 51: 51-58.
43. Gasparovic C, Arfai N, Smid N, Feeney DM. Decrease and recovery of N-acetylaspartate/ creatine in rat brain remote from focal injury. J Neurotrauma 2001; 18: 241-246.
44. Demougeot C, Garnier P, Mossiat C, Bertrand N, Giroud M, Beley A et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: Its relevance to studies of acute brain injury. J Neurochem 2001; 77: 408-415.
45. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 59: 55-61.
46. Girard N, Fogliarini C, Viola A, Confort-Gouny S, Fur YL, Viout P et al. MRS of normal and impaired fetal brain development. Eur J Radiol 2006; 57: 217-225.
47. Fatemi SH, Folsom TD, Reutiman TJ, Abu-Odeh D, Mori S, Huang H et al. Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr Res 2009; 112: 46-53.
48. Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, Yip L et al. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, firstepisode schizophrenia. Psychol Med 2008; 38: 877-885.
49. Cheung V, Chiu CP, Law CW, Cheung C, Hui CL, Chan KK et al. Positive symptoms and white matter microstructure in never-medicated first episode schizophrenia. Psychol Med 2011; 41: 1709-1719.
50. Wang Q, Cheung C, Deng W, Li M, Huang C, Ma X et al. White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment. Psychol Med 2013; 43: 2301-2309.
51. Radua J, Via E, Catani M, Mataix-Cols D. Voxel-based meta-analysis of regional white-matter volume differences in autism spectrum disorder versus healthy controls. Psychol Med 2011; 41: 1539-1550.
52. Cauda F, Costa T, Palermo S, D'Agata F, Diano M, Bianco F et al. Concordance of white matter and gray matter abnormalities in autism spectrum disorders: A voxel-based meta-analysis study. Hum Brain Mapp 2014; 35: 2073-2098.
53. Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000; 48: 861-873.
54. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cerebral Cortex 2002; 12: 386-394.
55. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 2002; 57: 127-138.
56. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133: 453-461.
57. Lima A, Sardinha VM, Oliveira AF, Reis M, Mota C, Silva MA et al. Astrocyte pathology in the prefrontal cortex impairs the cognitive function of rats. Mol Psychiatry 2014; 19: 834-841.
58. Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry GT, Buccafusca R et al. Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. Neuropsychopharmacology 2014; 39: 319-328.
59. Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: A review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005; 7: 1-10.
60. Zugno AI, Chipindo HL, Volpato AM, Budni J, Steckert AV, de Oliveira MB et al. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience 2014; 259: 223-231.
61. Zararsiz I, Kus I, Akpolat N, Songur A, Ogeturk M, Sarsilmaz M. Protective effects of omega-3 essential fatty acids against formaldehyde-induced neuronal damage in prefrontal cortex of rats. Cell Biochem Funct 2006; 24: 237-244.
62. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL. Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport 2003; 14: 2457-2461.
63. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Ppsychiatry 1992; 49: 206-215.
64. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 1987; 13: 643-668.
65. Yee N, Ribic A, de Roo CC, Fuchs E. Differential effects of maternal immune activation and juvenile stress on anxiety-like behaviour and physiology in adult rats: No evidence for the "double-hit hypothesis'. Behav Brain Res 2011; 224: 180-188.
66. White SW, Mazefsky CA, Dichter GS, Chiu PH, Richey JA, Ollendick TH. Socialcognitive, physiological, and neural mechanisms underlying emotion regulation impairments: Understanding anxiety in autism spectrum disorder. Int J Dev Neurosci 2014; 39: 22-36.
67. McAlonan GM, Daly E, Kumari V, Critchley HD, van Amelsvoort T, Suckling J et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain 2002; 125: 1594-1606.
68. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Rev 2000; 31: 371-384.
69. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: Anxiety as the best symptom predictor. J Nerv Ment Dis 2001; 189: 669-675.
70. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 2001; 156: 117-154.
71. Watanabe A, Toyota T, Owada Y, Hayashi T, Iwayama Y, Matsumata M et al. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol 2007; 5: E297.
72. Jasarevic E, Hecht PM, Fritsche KL, Beversdorf DQ, Geary DC. Dissociable effects of dorsal and ventral hippocampal DHA content on spatial learning and anxiety-like behavior. Neurobiol Learn Mem 2014; 116C: 59-68.
73. Pederzolli CD, Rockenbach FJ, Zanin FR, Henn NT, Romagna EC, Sgaravatti AM et al. Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis 2009; 24: 283-298.
74. Deslauriers J, Racine W, Sarret P, Grignon S. Preventive effect of alpha-lipoic acid on prepulse inhibition deficits in a juvenile two-hit model of schizophrenia. Neuroscience 2014; 272: 261-270.
75. Grottick AJ, Bagnol D, Phillips S, McDonald J, Behan DP, Chalmers DT et al. Neurotransmission- And cellular stress-related gene expression associated with prepulse inhibition in mice. Brain Res Mol Brain Res 2005; 139: 153-162.
76. O'Neill HC, Schmitt MP, Stevens KE. Lithium alters measures of auditory gating in two strains of mice. Biol Psychiatry 2003; 54: 847-853.
77. Fortier ME, Joober R, Luheshi GN, Boksa P. Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring. J Psychiatr Res 2004; 38: 335-345.
78. Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol 2013; 14: R82.
79. Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res 2007; 91: 51-61.
80. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: Insights from animal models. Schizophr Bull 2011; 37: 484-492.
81. Nguyen R, Morrissey MD, Mahadevan V, Cajanding JD, Woodin MA, Yeomans JS et al. Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia. J Neurosci 2014; 34: 14948-14960.
82. Nousiainen HO, Quintero IB, Myohanen TT, Voikar V, Mijatovic J, Segerstrale M et al. Mice deficient in transmembrane prostatic acid phosphatase display increased GABAergic transmission and neurological alterations. PloS One 2014; 9: E97851.
83. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol Psychiatry 2013; 74: 106-112.
84. Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008; 33: 441-456.
85. Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010; 30: 1270-1287.
86. Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology 2012; 37: 956-969.
87. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res 1986; 396: 157-198.
88. Peleg-Raibstein D, Hauser J, Llano Lopez LH, Feldon J, Gargiulo PA, Yee BK. Baseline prepulse inhibition expression predicts the propensity of developing sensitization to the motor stimulant effects of amphetamine in C57BL/6 mice. Psychopharmacology (Berl) 2013; 225: 341-352.
89. Missault S, Van den Eynde K, Vanden Berghe W, Fransen E, Weeren A, Timmermans JP et al. The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain Behav Immun 2014; 42: 138-146.
90. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL et al. Obesity among those with mental disorders: A National Institute of Mental Health meeting report. Am J Prev Med 2009; 36: 341-350.
91. Bronson SL, Bale TL. Prenatal stress-induced increases in placental inflammation and offspring hyperactivity are male-specific and ameliorated by maternal antiinflammatory treatment. Endocrinology 2014; 155: 2635-2646.
92. Bergeron JD, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T et al. White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Dev Neurosci 2013; 35: 504-515.